Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis

• Status: Terminated
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using topical aminolevulinic acid may be effective against actinic keratosis.

PURPOSE: This randomized clinical trial is studying how well different photodynamic therapy regimens using topical aminolevulinic acid work in treating patients with actinic keratosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Roswell Park Cancer Institute
• Collaborator: National Cancer Institute (NCI)
• Treatments: Aminolevulinic Acid

Criteria

DISEASE CHARACTERISTICS:

• Actinic keratosis lesion located in any of the following body sites:

• Stratum 1*: face and neck, scalp, or upper torso

• At least 1 clinically evident thin actinic keratosis on each side of the midline of any of the above areas

• Stratum 2*: arms or legs

• At least 1 clinically evident thick actinic keratosis on each arm or leg NOTE: *One patient may be in one or both strata depending on the location of the lesion(s)

• Lesions to be treated on this protocol must not have been previously treated by other modalities for at least 2 months prior to study entry

PATIENT CHARACTERISTICS:

• No porphyria or known hypersensitivity to porphyrins

• No known photosensitivity disease

• No known sensitivity to any components of aminolevulinic acid topical solution

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

• Other concurrent topical therapies at lesion sites other than those used in this protocol are allowed

• No other concurrent photosensitizer drugs